USANA Health Sciences (NYSE:USNA) Stock Price Passes Above Two Hundred Day Moving Average – Here’s What Happened

Shares of USANA Health Sciences, Inc. (NYSE:USNA) crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $19.60 and traded as high as $22.80. USANA Health Sciences shares last traded at $22.3870, with a volume of 97,300 shares changing hands.

Analyst Upgrades and Downgrades

USNA has been the topic of a number of analyst reports. Wall Street Zen raised shares of USANA Health Sciences from a “hold” rating to a “buy” rating in a research note on Saturday, June 20th. Weiss Ratings reiterated a “sell (d)” rating on shares of USANA Health Sciences in a research note on Wednesday, June 24th. Finally, Zacks Research downgraded shares of USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 22nd. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Reduce”.

USANA Health Sciences Trading Up 0.2%

The company has a market cap of $409.40 million, a price-to-earnings ratio of 47.18, a PEG ratio of 0.88 and a beta of 0.73. The business has a fifty day moving average of $19.81 and a two-hundred day moving average of $19.62.

USANA Health Sciences (NYSE:USNA) last posted its quarterly earnings data on Tuesday, May 5th. The company reported $0.61 EPS for the quarter, beating analysts’ consensus estimates of $0.44 by $0.17. USANA Health Sciences had a return on equity of 6.21% and a net margin of 0.96%.The business had revenue of $250.22 million during the quarter, compared to analysts’ expectations of $240.99 million. USANA Health Sciences has set its FY 2026 guidance at 1.950-2.290 EPS. On average, research analysts forecast that USANA Health Sciences, Inc. will post 2.12 EPS for the current fiscal year.

Insider Activity at USANA Health Sciences

In other USANA Health Sciences news, Director John Turman Fleming sold 2,450 shares of the stock in a transaction on Monday, June 1st. The shares were sold at an average price of $17.93, for a total transaction of $43,928.50. Following the transaction, the director directly owned 4,230 shares of the company’s stock, valued at $75,843.90. This trade represents a 36.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Brent Neidig sold 5,002 shares of the business’s stock in a transaction dated Tuesday, June 16th. The stock was sold at an average price of $19.45, for a total transaction of $97,288.90. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 17,660 shares of company stock valued at $336,579. Insiders own 0.82% of the company’s stock.

Hedge Funds Weigh In On USANA Health Sciences

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Versant Capital Management Inc boosted its stake in shares of USANA Health Sciences by 1,472.3% in the second quarter. Versant Capital Management Inc now owns 1,588 shares of the company’s stock worth $34,000 after acquiring an additional 1,487 shares during the last quarter. National Bank of Canada FI raised its stake in USANA Health Sciences by 166.6% in the 3rd quarter. National Bank of Canada FI now owns 1,922 shares of the company’s stock valued at $53,000 after purchasing an additional 1,201 shares during the last quarter. State of Wyoming purchased a new position in USANA Health Sciences in the 1st quarter valued at $57,000. Tower Research Capital LLC TRC lifted its holdings in USANA Health Sciences by 382.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,398 shares of the company’s stock valued at $73,000 after purchasing an additional 1,901 shares in the last quarter. Finally, Parallel Advisors LLC boosted its stake in USANA Health Sciences by 1,354.3% during the 4th quarter. Parallel Advisors LLC now owns 3,854 shares of the company’s stock worth $76,000 after purchasing an additional 3,589 shares during the last quarter. Hedge funds and other institutional investors own 54.25% of the company’s stock.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.